CTIS2024-513214-34-00
Active, not recruiting
Phase 1
A multi-center, single-arm, open-label study to evaluate tolerability, safety, and efficacy of topical MOB015B solution in the treatment of mild to moderate distal subungual onychomycosis (DSO) in subjects aged 6-17 years
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Distal Subungual Onychomycosis
- Sponsor
- Moberg Pharma AB (publ)
- Enrollment
- 26
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male or female subjects 6 to 17 years of age (inclusive)., 2\. Distal subungual onychomycosis of at least one of the great toenail(s) affecting at least 20% of the target nail to a maximum of 50% and at least 3 mm of unaffected proximal nail., 3\. Positive culture of dermatophyte and positive KOH microscopy in samples taken from the same great toenail., 4\. Signed written informed assent/consent., 5\. Evidence of ability of the great toenail to grow (eg, subject reports cutting toenails at least monthly)., 6\. Able to comply with the study protocol (in the opinion of the investigator).
Exclusion Criteria
- •1\. Proximal subungual onychomycosis, superficial white onychomycosis, significant dystrophy, severe onychorrhexis, or anatomic abnormalities of the great toenail(s) that in the opinion of the investigator would impair clinical evaluation of onychomycosis., 10\. Previous target toenail surgery with any residual disfigurement., 11\. Topical treatment of the toenails with other antifungal medication within 4 weeks before screening/Visit 1\., 12\. Use of systemic antifungal treatment within 6 months before screening/Visit 1\., 13\. History or ongoing/active moderate to severe Moccasin tinea pedis., 14\. Having a diagnosis of type 1 diabetes or uncontrolled type 2 diabetes., 15\. Known immunodeficiency., 16\. Known human immunodeficiency virus (HIV) infection., 17\. Participation in another clinical study with an investigational drug or device during the previous 3 months before screening/Visit 1\., 18\. Known allergy to any of the tested treatment products., 19\. A positive pregnancy test at enrollment/baseline (Visit 2\)., 2\. Distal subungual onychomycosis where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 3 mm)., 20\. Female subjects physiologically capable of becoming pregnant but are unwilling to refrain from sexual intercourse during the whole study duration or unwilling to use acceptable methods of contraception as agreed with the investigator., 21\. Female subjects who are pregnant, breastfeeding mothers, those planning a pregnancy during the study or who become pregnant., 3\. Target toenail with greater than 50% disease involvement., 4\. Target toenail thickness more than 3 mm., 5\. Spike” of onychomycosis extending to eponychium of the target nail., 6\. Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail., 7\. Conditions other than distal subungual onychomycosis known to cause abnormal nail appearance, presence of melanonychia or subungual hematoma that could obscure visualization of nail clearing., 8\. Other microbial infections of the target toenail, for example, candida or mold infections without isolation of a dermatophyte., 9\. Subjects with psoriasis, lichen planus, history of mucocutaneous candidiasis, or other conditions that affect nail appearance and/or growth.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
on-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mild to moderate fungal infection of the nail in subjects aged 6-17 yearsDistal Subungual OnychomycosisTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2022-001797-59-ITMoberg Pharma AB30
Active, not recruiting
Phase 1
on-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mild to moderate fungal infection of the nail in subjects aged 6-17 yearsEUCTR2022-001797-59-DKMoberg Pharma AB (publ.)30
Active, not recruiting
Phase 1
on-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mild to moderate fungal infection of the nail in subjects aged 6-17 yearsDistal Subungual OnychomycosisMedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2022-001797-59-PLMoberg Pharma AB (publ.)30
Active, not recruiting
Phase 1
on-controlled, open-label study to evaluate tolerability, safety, and efficacy of MOB015B solution for external use in the treatment of mild to moderate fungal infection of the nail in subjects aged 6-17 yearsEUCTR2022-001797-59-ISMoberg Pharma AB (publ.)30
Active, not recruiting
Not Applicable
A multi-center, open-label, single-arm study to evaluate hormone and lipid levels in male subjects with partial onset seizures after a switch of treatment from carbamazepine as adjunctive treatment to levetiracetam to lacosamide as adjunctive treatment to levetiracetam.EUCTR2010-022534-84-DECB Pharma SA28